Surfing the MASH Tsunami
Driving the Discussion in Fatty Liver Disease. Join hepatology researcher and Key Opinion Leader Jörn Schattenberg, Liver Wellness Advocate Louise Campbell, and Forecasting and Pricing Guru Roger Green and a global group of Key Opinion Leaders and patient advocates as they discuss key issues in Fatty Liver disease, including epidemiology, drug development, clinical pathways, non-invasive testing, health economics and regulatory issues, from their own unique perspectives on the Surfing the MASH Tsunami podcast. #MASH #MAFLD #FattyLiver #livertwitter #AASLD #GlobalLiver #NoNASH #EASL
Episodes
1073 episodes
S6.14.3 - Louise and Roger React to Empowered SLD Patient Advocates
The original roundtable has three segments. Surfing the MASH Tsunami is preempting the third segment, which will be posted next week, to share our co-hosts' reactions to the positivity and energy they felt from a group of empowered SLD advocate...
•
Season 6
•
Episode 14
•
20:16
S6.14.2 - Goals of the Stephen A. Harrison Patient Advocacy Fellowship Program
In June, the Fatty Liver Foundation officially launched the Stephen A. Harrison Patient Advocacy program and announced its first class of 20 Fellows. In today's conversation, the program's organizers, Fatty Liver Foundation President Wayne Eskr...
•
Season 6
•
Episode 14
•
19:14
S6.14.1 - How the Harrison Patient Advocacy Fellowship Came To Be
In June, the Fatty Liver Foundation officially launched the Stephen A. Harrison Patient Advocacy program and announced its first class of 20 Fellows. In today's conversation, Louise Campbell and Roger Green interview the founders to learn what ...
•
Season 6
•
Episode 14
•
38:22
S6.14 - Introducing the Dr. Stephen A. Harrison Patient Advocacy Fellowship Program
00:00:00 - Surf's Up: Season 6 Episode 14Louise Campbell and Roger Green interview key players in the inaugural Dr. Stephen A. Harrison Patient Advocacy Fellowship program, including Wayne Eskridge of the Fatty Liver Foundation (FLF), which...
•
Season 6
•
Episode 14
•
1:07:34
S6.13.3 - Major Issues in MASH-ville: US Government Chaos and Scanning Market Dynamism
This discussion on ways to improve MASH patient management comes from the early July roundtable on "Major Issues of the First Six Months of 2025." As a reminder, that roundtable included the three co-hosts (Louise, Jörn Schattenberg and Roger G...
•
Season 6
•
Episode 13
•
37:13
S6.13.2 - Newsmakers: Updating Our Approach to Screening for Advanced Liver Disease
Last month, The Lancet posted online an article from Stine Johansen, Fredrik Åberg, Emmanuel Tsochatzis and Aleksander Krag, titled "Screening for Advanced Liver Disease." The article aims to update the Wilson and Jungner criteria, initially de...
•
Season 6
•
Episode 13
•
20:19
S6.13.1 - Major Issues in MASH-ville: Developing a More Integrated Approach to MASH Patient Management
This discussion on ways to improve MASH patient management comes from the early July roundtable on "Major Issues of the First Six Months of 2025." As a reminder, that roundtable included the three co-hosts (Louise, Jörn Schattenberg and Roger G...
•
Season 6
•
Episode 13
•
19:48
S6.13 - Locating MASH patients, Population Screening for Advanced Disease, Impact of Washington on Americans' Health
00:00:00 - Surf's Up: Season 6 Episode 13 Louise Campbell, Jörn Schattenberg and Roger Green continue their discussion of some major issues from earlier this year, while co-authors Aleksander Krag and Stine Johanset join Roger to discu...
•
Season 6
•
Episode 13
•
1:13:53
S6.12.3 - After the Semaglutide Approval: What Next For MASH Therapy?
Key Opinion Leaders Manal Abdelmalek, Naim Alkhouri, Scott Isaacs and Zobair Younossi join Roger Green to discuss the FDA's approval of semaglutide for patients with non-cirrhotic MASH. This conversation centers on the roles that new technologi...
•
Season 6
•
Episode 12
•
21:39
S6.12.2 - After the Semaglutide Approval: Expanding MASH Awareness Will Change Medical Practices
Key Opinion Leaders Manal Abdelmalek, Naim Alkhouri, Scott Isaacs and Zobair Younossi join Roger Green to discuss the FDA's approval of semaglutide for patients with non-cirrhotic MASH. This conversation focuses on how the US healthcare system ...
•
Season 6
•
Episode 12
•
22:58
S6.12.1 - After the Semaglutide Approval: Impact on Patients and Pharmacotherapy
Key Opinion Leaders Manal Abdelmalek, Naim Alkhouri, Scott Isaacs and Zobair Younossi join Roger Green to discuss FDA's approval of semaglutide for patients with non-cirrhotic MASH. This conversation focuses on benefits for patients and w...
•
Season 6
•
Episode 12
•
24:35
6.12 - A Second US Drug Approval! What Semaglutide's Success Portends For MASLD Care in the US
00:00:00 - Surf's Up, Season 6, Episode 12This week's episode is a special three-part roundtable on the implications of the FDA's recent approval of semaglutide. Naim Alkhouri, Manal Abdelmalek, Scott Isaacs and Zobair Younossi join Roger G...
•
Season 6
•
Episode 12
•
1:04:23
6.11.3 - Expert: Emily Andaya Asks Why There Is No "L" In the (Multi-Meatbolic) CKM Initiative
This week's expert interview is with Dr. Emily Andaya, Medical Director of the Cardiovascular Program at Major Health Partners of Shelbyville, IN. She joins Louise Campbell and Roger Green to discuss the American Heart Assocation's CKM initiati...
•
Season 6
•
Episode 11
•
41:03
6.11.2 - Multi-Metabolic Week Part II: Benefits of the Multi-Metabolic Approach
Multi-Metabolic Week focuses on the idea that MASLD and MASH are elements in a systemic set of Multi-Metabolic issues. This conversation is the second of two looking at the concept of the "Multi-Metabolic Clinic," a clinic that treats the entir...
•
Season 6
•
Episode 11
•
43:59
6.11.1 - Multi-Metabolic Week Part I: Role of MASLD In Multi-Metabolic Clinics
Multi-Metabolic Week focuses on the idea that MASLD and MASH are elements in a systemic set of Multi-Metabolic issues. This conversation is the first of two looking at the concept of the "Multi-Metabolic Clinic," a clinic that treats the entire...
•
Season 6
•
Episode 11
•
37:34
6.11 - Multi-Metabolic Practices Integrate MASLD with Other Non-Communicable Diseases
00:00:00 - Surf's Up: Season 6, Episode 11 This week, we modify our usual episode structure to focus on multi-metabolic practices and constructs. The multi-metabolic practices covered this week are run by non-hepatologists who have ...
•
Season 6
•
Episode 11
•
1:49:45
6.10.3 - Expert: Tim Jobson on Using Basic Data and Analytics to Identify At-Risk Patients
This week's expert is Tim Jobson, Medical Director of Predictive Health Intelligence, a UK-based consultancy. Tim joins Louise Campbell and Roger Green to share an update on PHI's Somerset UK project and other activities. The Somers...
•
Season 6
•
Episode 10
•
37:16
6.10.2 - Newsmakers: LiverRight Launches America's First Virtual Hepatology Clinic
Roger Green talks with LiverRight CEO Brandon Tudor and Chief Medical Officer Alexander Lalos about the launch of LiverRight, America's first virtual hepatology clinic, which has recently begun treating patients.Brandon starts the conver...
•
Season 6
•
Episode 10
•
30:49
6.10.1 - FIrst Six Months, Part I: The Promise of Proteomics For Developing Individualized Treatment Plans
This conversation is the first segment of SurfingMASH’s July discussion of key events from the first six months of 2025. Co-hosts Jörn Schattenberg, Louise Campbell and Roger Green each chose one topic of personal interest. Today, Jörn Sc...
•
Season 6
•
Episode 10
•
27:36
6.10 - New Approaches to Patient Care: NIT-driven drug choices, Virtual Clinics, Large-Scale Screening
00:00 - Surf's Up 6.10.1This conversation covers three topics. Jörn Schattenberg discusses two papers that suggest an exciting role NITs might play in future prescribing decisions, two executives from LiverRight describe the U.S.'s first vi...
•
Season 6
•
Episode 10
•
1:32:25
6.9.3 - Expert: Naim Alkhouri Discusses His Long Friendship with Stephen Harrison and His New Role at Summit Clinical Research
Hepatologist and hepatology key opinion leader Naim Alkhouri joins Roger Green to remember his longstanding relationship with Stephen Harrison, announce his new role as Chief Academic Officer at Summit Clinical Research and share how, in this r...
•
Season 6
•
Episode 9
•
29:12
6.9.2 - Newsmaker: Fatty Liver Alliance President Mike Betel Discusses His 3rd Annual 30-Day Glucose Challenge
Fatty Liver Alliance President Mike Betel joins Roger Green to discuss his recent completion of the 3rd Annual Glucose Challenge, an event every July where Mike wears a continuous glucose monitor (CGM) device for a month, conducts food experime...
•
Season 6
•
Episode 9
•
39:31
6.9.1 - #SLDThinkTank2025, Part III: Unique Challenge of Nutrition Management and Role Politicians Can Play
This conversation is the third and final segment of SurfingMASH’s July discussion of #SLDThinkTank 2025. In addition to co-hosts Jörn Schattenberg, Louise Campbell and Roger Green, panelists include Dr. Kristina Curtis of Applied Behaviour Chan...
•
Season 6
•
Episode 9
•
23:35
6.9 - Complexities of Behavior Change, Devices That Can Help, Future of Clinical Trials and MedEd
00:00:00 - Surf's Up: Episode 6.9This conversation covers three topics. The first discusses the challenges of behavior change in dietary habits and ways governments can help, the second looks at what one can learn from wearing a CGM for 30 ...
•
Season 6
•
Episode 9
•
1:17:21
6.8.3 - Deep Dive into Drug Development IV: Other Modes Of Action; Metabolic vs. Pleiotropic Effects
This conversation is the fourth and final segment of SurfingMASH’s April discussion of drug development in memory of Stephen A. Harrison. In addition to co-hosts Jörn Schattenberg, Louise Campbell and Roger Green, panelists incl...
•
Season 6
•
Episode 8
•
16:59